EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...
SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...
XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...
Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...
Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...
We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...
Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...
Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy ...
Pharmaceutical companies raise drug prices in U.S.; Korea faces minimal impact Global drug price hikes by major firms ...
Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...
Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...